Prognostic significance of p53 and Ki67 proteins expression in greek gastric cancer patients

Acta Chirurgica Belgica

Volumn 109, Issue 5, 2009, Pages 606-611

  Tzanakis, N E ^a   Peros, G ^a   Karakitsos, P ^b   Giannopoulos, G A ^a,d   Efstathiou, S P ^c   Rallis, G ^a   Tsigris, Chr ^a   Kostakis, A ^a   Nikiteas, N I ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Internal Medicine

^d NONE

Author keywords

Gastric cancer; Tumor staging

Indexed keywords

EID: 73049099837     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2009.11680496     Document Type: Article

References (40)

1. SIEWERT J. R., SENDLER A. The current management of gastric cancer. Adv Surg, 1999, 33:69-93.
2. GILL S., SHAH A., LE N., COOK E. F., YOSHIDA E. M. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol, 2003, 21: 2070-2076.
3. MC CULLOCH P., TAGGART T., OCHIAI A., O'dowd G., NASH J., SASAKO M. c-erbB2 and p53 expression are not associated with stage progression of gastric cancer in Britain or Japan. Eur J Surg Oncol, 1997, 23:304-309.
4. SCHUHMACHER C. P., FINK U., BECKER K. et al. Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer, 2001, 91: 918-927.
5. DICKEN B. J., SAUNDERS L. D., JHANGRI G. S. et al. Gastric cancer: establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol, 2004, 11:629-635.
6. ZOLOTA V., BATISTATOU A., TSAMANDAS A. C., ILIOPOULOS G., SCOPA C. D., BONIKOS D. S. Immunohistochemical expression of TGF-betal, p21WAFl, p53, Ki67, and angiogenesis in gastric carcinomas: a clinicopathologic study. Int J Gastrointest Cancer, 2002, 32:83-89.
7. STEELE R. J., THOMPSON A. M., HALL P. A., LANE D. P. The p53 tumour suppressor gene. Br J Surg, 1998, 85:1460-1467.
8. FENOGLIO-PREISER C. M., WANG J., STEMMERMANN G. N., NOFFSINGER A. TP53 and gastric carcinoma: a review. Hum Mutat, 2003, 21: 258-270.
9. WONG S. K., SEOW-CHOEN F., LEONG A. P., HO Y. H., Aw S. E. Mutant plasma p53 protein levels: prognostication in colorectal carcinoma. Br J Surg, 1997, 84:664-665.
10. HASHIMOTO N., TACHIBANA M., DHAR D. K., YOSHIMURA H., NAGASUE N. Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: their relationship with clinicopathologic characteristics. Ann Surg Oncol, 1999, 6:489-494.
11. REED W., HANNISDAL E., BOEHLER P. J., GUNDERSEN S., HOST H., MARTHIN J. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 2000, 88:804-813.
12. MAEHARA Y., TOMODA M., HASUDA S. el al. Prognostic value of p53 protein expression for patients with gastric cancer - a multivariate analysis. Br J Cancer, 1999, 79:1255-1261.
13. MAEHARA Y., KAKEJI Y., WATANABE A. et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer, 1999, 85:302-308.
14. ROVIELLO F., MARRELLI D., VINDIGNI C., DE STEFANO A., SPINA D., PINTO E. P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol, 1999, 6:739-745.
15. LEE K. E., LEE H. J., KIM Y. H. et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol, 2003, 33: 173-179.
16. LIM B. H., SOONG R., GRIEU F., ROBBINS P. D., HOUSE A. K., IACOPETTA B. J. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer, 1996, 69:200-204.
17. BROWN D. C., GATTER K. C. Monoclonal antibody Ki-67: its use in histopathology. Histopathology, 1990, 17:489-503.
18. VICTORZON M., ROBERTS P. J., HAGLUND C., VON BOGUSLAWSKY K., NORDLING S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology, 1996, 53:182-191.
19. VICTORZON M., ROBERTS P. J., HAGLUND C., VON BOGUSLAWSKY K., NORDLING S. Ki-67, ploidy and S-phase fraction as prognostic factors in gastric cancer. Anticancer Res, 1997, 17:2923-2926.
20. OSHIMA C. T., IRIYA K., FORONES N. M. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma, 2005, 52:420-424.
21. YONEMURA Y., OOYAMA S., SUGIYAMA K. et al. Growth fractions in gastric carcinomas determined with monoclonal antibody Ki-67. Cancer, 1990, 65:1130-1134.
22. LAUREN P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So-Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta Pathol Microbiol Scand, 1965, 64:31-49.
23. MING S. C. Gastric carcinoma. A pathobiological classification. Cancer, 1977, 39:2475-2485.
24. TAKAGANE A., TERASHIMA M., ABE K. et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer, 1999, 2:122-128.
25. SANCER AJCO. Stomach. In: GREENE F. (ed.). AJCC Cancer Staging Manual. 5 edn. Philadelphia: Lippincot-Raven, 1997:71-76.
26. DIEZ M., MEDRANO M. J., GUTIERREZ A. et al. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy. Anticancer Res, 2000, 20:3929-3933.
27. KIM J. H., UHM H. D., GONG S. J. et al. Relationship between p53 overexpression and gastric cancer progression. Oncology, 1997, 54:166-170.
28. AL-MOUNDHRI M. S., NIRMALA V., AL-HADABI I. et al. The prognostic significance of p53, p27 kipl, p21 wafl, HER-2/neu, and Ki67 proteins expression in gastric cancer: a clinicopathological and immunohistochemical study of 121 Arab patients. J Surg Oncol, 2005, 91:243-252.
29. WANG Z., IKEGUCHI M., MAETA M., KAIBARA N. The correlation between the expression of p53 protein and DNA ploidy in patients with gastric cancer that has invaded the serosa. Anticancer Res, 1997, 17:3701-3705.
30. GOMYO Y., IKEDA M., OSAKI M. et al. Expression of p21 (wafl/cipl/sdil), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer, 1997, 79:2067-2072.
31. KAYE P. V., RADEBOLD K., ISAACS S., DENT D. M. Expression of p53. and p21wafl/cipl in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur J Surg Oncol, 2000, 26:39-43.
32. MULLER W., BORCHARD F. Prognostic influence of p53 expression in gastric cancer. J Pathol, 1996, 178:255-258.
33. SANZ-ORTEGA J., STEINBERG S. M., MORO E. et al. Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol, 2000, 15:455-462.
34. PINTO-DE-SOUSA J., DAVID L., SEIXAS M., PIMENTA A. Clinicopathologic profiles and prognosis of gastric carcinomas from the cardia, fundus/body and antrum. Dig Surg, 2001, 18:102-110.
35. TANG H., HOKITA S., CHE X. et al. Comparison of p53 expression in proximal and distal gastric cancer: histopathologic correlation and prognostic significance. Ann Surg Oncol, 1997, 4:470-474.
36. OZGUROGLU M., DEMIR G. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer, 1999, 86:547-549.
37. GILLILAND R., WILLIAMSON K. E., WILSON R. H., ANDERSON N. H., HAMILTON P. W. Colorectal cell kinetics. Br J Surg, 1996, 83:739-749.
38. KIM J. Y., CHO H. J. DNA ploidy patterns in gastric adenocarcinoma. J Korean Med Sci, 2000, 15:159-166.
39. MAEDA K, CHUNG Y. S, TAKATSUKA S. et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer, 1995, 72:319-323.
40. MORI M., KAKEJI Y., ADACHI Y. et al. The prognostic significance of proliferating cell nuclear antigen in clinical gastric cancer. Surgery, 1993, 113: 683-690.